Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beth Israel Deaconess Medical Center
With
Boston Children's Hospital
Bristol-Myers Squibb
Brigham and Women's Hospital
Patients with COVID-19 who are admitted with respiratory distress will be considered for enrollment on this study. Patients will be screened and then if they meet eligibility criteria will be enrolled. Abatacept will be administered on Day 1 at a dose of 10 mg/kg. Patients will then be followed closely through 90 days post-treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be at least 18 years old.
Confirmed SARS-CoV-2 infection, confirmed by polymerase chain reaction (PCR) \</=4 days prior to enrollment
Evidence of respiratory distress including SpO2 \</=93% on room air.
Radiographic evidence of pulmonary infiltrates.
Ability to understand and the willingness to provide informed consent.
You may not be if
Patients already intubated/mechanically ventilated at screening will not be eligible.
Patients with uncontrolled severe bacterial or fungal infections at the time of enrollment.
Pregnant or breastfeeding
Clareo Health | Abatacept for Patients With COVID-19 and Respiratory Distress
